Author pages are created from data sourced from our academic publisher partnerships and public sources.
Physical activity and liver diseases
Regular physical activity beneficially impacts the risk of onset and progression of several chronic diseases. However, research regarding the effects of exercising on chronic liver diseases is… Expand
Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification
Hepatocellular carcinoma (HCC) is one of the commonest causes of death from cancer. A plethora of metabolomic investigations of HCC have yielded molecules in biofluids that are both up‐ and… Expand
Reply to «Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER,…
Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease
Depending on tumor burden, hepatic function and patients’ performance status, hepatocellular carcinoma is treated by surgery, local procedures, systemic therapy or palliation. The majority of… Expand
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
BACKGROUND & AIMS Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection. In nine phase II or… Expand
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.
BACKGROUND/AIMS While several risk factors for the histological progression of chronic hepatitis C have been identified, the contribution of HCV genotypes to liver fibrosis evolution remains… Expand
Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.
- Anne-Christine Piguet, D. Semela, +5 authors Jean‐François Dufour
- Journal of hepatology
- 1 July 2008
BACKGROUND/AIMS Hepatocellular carcinoma (HCC) is resistant to chemotherapy. We reported that sirolimus, an mTOR inhibitor, has antiangiogenic properties in HCC. Since antiangiogenic therapy may… Expand
Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development
Background Vitamin D insufficiency has been associated with the occurrence of various types of cancer, but causal relationships remain elusive. We therefore aimed to determine the relationship… Expand
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma.
BACKGROUND & AIMS Recently, genetic variations in MICA (lead single nucleotide polymorphism [SNP] rs2596542) were identified by a genome-wide association study (GWAS) to be associated with hepatitis… Expand
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon‐alpha and ribavirin therapy
Elevated serum ferritin levels may reflect a systemic inflammatory state as well as increased iron storage, both of which may contribute to an unfavorable outcome of chronic hepatitis C (CHC). We… Expand